{"id":"https://openalex.org/W2000406055","doi":"https://doi.org/10.1055/s-0030-1248313","title":"Long-Term Assessment of Asenapine vs. Olanzapine in Patients with Schizophrenia or Schizoaffective Disorder","display_name":"Long-Term Assessment of Asenapine vs. Olanzapine in Patients with Schizophrenia or Schizoaffective Disorder","alternate_titles":[],"publication_year":2010,"publication_date":"2010-03-04","ids":{"openalex":"https://openalex.org/W2000406055","doi":"https://doi.org/10.1055/s-0030-1248313","mag":"2000406055","pmid":"https://pubmed.ncbi.nlm.nih.gov/20205074"},"language":"en","primary_location":{"id":"doi:10.1055/s-0030-1248313","doi":"https://doi.org/10.1055/s-0030-1248313","is_oa":false,"landing_page_url":"https://doi.org/10.1055/s-0030-1248313","pdf_url":null,"source":{"id":"https://openalex.org/S4122505","display_name":"Pharmacopsychiatry","issn_l":"0176-3679","issn":["0176-3679","1439-0795"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320000","host_organization_name":"Thieme Medical Publishers (Germany)","host_organization_lineage":["https://openalex.org/P4310320000"],"host_organization_lineage_names":["Thieme Medical Publishers (Germany)"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacopsychiatry","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2000406055"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5029755078","display_name":"Joep H. Schoemaker","orcid":"https://orcid.org/0000-0001-7954-0840","observed_orcids":["https://orcid.org/0000-0001-7954-0840"]},"institutions":[{"id":"https://openalex.org/I4210162999","display_name":"MSD (Netherlands)","ror":"https://ror.org/05y28vr04","country_code":"NL","type":"company","lineage":["https://openalex.org/I1285764155","https://openalex.org/I4210162999"]},{"id":"https://openalex.org/I4405279838","display_name":"Organon (Netherlands)","ror":"https://ror.org/02388np20","country_code":"NL","type":"company","lineage":["https://openalex.org/I4405279838"]}],"countries":["NL"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"J. Schoemaker","raw_affiliation_strings":["Schering-Plough (formerly NV Organon), now Merck Sharp & Dohme, Oss, The Netherlands. joep.schoemaker@merck.com","Schering-Plough (formerly NV Organon), now Merck Sharp & Dohme, Oss, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Schering-Plough (formerly NV Organon), now Merck Sharp & Dohme, Oss, The Netherlands. joep.schoemaker@merck.com","institution_ids":["https://openalex.org/I4210162999","https://openalex.org/I4405279838"]},{"raw_affiliation_string":"Schering-Plough (formerly NV Organon), now Merck Sharp & Dohme, Oss, The Netherlands","institution_ids":["https://openalex.org/I4210162999","https://openalex.org/I4405279838"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110050916","display_name":"Dieter Naber","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I159176309","display_name":"Universit\u00e4t Hamburg","ror":"https://ror.org/00g30e956","country_code":"DE","type":"education","lineage":["https://openalex.org/I159176309"]}],"countries":["DE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"D. Naber","raw_affiliation_strings":["University of Hamburg-Eppendorf, Hamburg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Hamburg-Eppendorf, Hamburg, Germany","institution_ids":["https://openalex.org/I159176309"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006705144","display_name":"Peter Vrijland","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210162999","display_name":"MSD (Netherlands)","ror":"https://ror.org/05y28vr04","country_code":"NL","type":"company","lineage":["https://openalex.org/I1285764155","https://openalex.org/I4210162999"]},{"id":"https://openalex.org/I4405279838","display_name":"Organon (Netherlands)","ror":"https://ror.org/02388np20","country_code":"NL","type":"company","lineage":["https://openalex.org/I4405279838"]}],"countries":["NL"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"P. Vrijland","raw_affiliation_strings":["Schering-Plough (formerly NV Organon), now Merck Sharp & Dohme, Oss, The Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Schering-Plough (formerly NV Organon), now Merck Sharp & Dohme, Oss, The Netherlands","institution_ids":["https://openalex.org/I4210162999","https://openalex.org/I4405279838"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084351087","display_name":"John Panagides","orcid":"https://orcid.org/0000-0002-8008-7649","observed_orcids":["https://orcid.org/0000-0002-8008-7649"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"J. Panagides","raw_affiliation_strings":["Schering-Plough (formerly Organon), now Merck, Summit, New Jersey, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Schering-Plough (formerly Organon), now Merck, Summit, New Jersey, USA","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"last","author":{"id":null,"display_name":"R. Emsley","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I26092322","display_name":"Stellenbosch University","ror":"https://ror.org/05bk57929","country_code":"ZA","type":"education","lineage":["https://openalex.org/I26092322"]}],"countries":["ZA"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"R. Emsley","raw_affiliation_strings":["University of Stellenbosch, Cape Town, South Africa"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Stellenbosch, Cape Town, South Africa","institution_ids":["https://openalex.org/I26092322"]}]}],"institutions":[],"countries_distinct_count":4,"institutions_distinct_count":5,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":7.379,"has_fulltext":false,"cited_by_count":90,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.97716787,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":99},"biblio":{"volume":"43","issue":"04","first_page":"138","last_page":"146"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10854","display_name":"Bipolar Disorder and Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/asenapine","display_name":"asenapine","score":1.0},{"id":"https://openalex.org/keywords/olanzapine","display_name":"olanzapine","score":1.0},{"id":"https://openalex.org/keywords/schizophrenia","display_name":"schizophrenia","score":0.984000027179718},{"id":"https://openalex.org/keywords/schizoaffective-disorder","display_name":"schizoaffective disorder","score":1.0},{"id":"https://openalex.org/keywords/long-term-antipsychotic-treatment","display_name":"long-term antipsychotic treatment","score":0.7820000052452087},{"id":"https://openalex.org/keywords/weight-gain","display_name":"weight gain","score":0.7699999809265137},{"id":"https://openalex.org/keywords/extrapyramidal-symptoms","display_name":"extrapyramidal symptoms","score":0.9959999918937683},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.7289999723434448},{"id":"https://openalex.org/keywords/positive-and-negative-syndrome-scale","display_name":"PANSS","score":0.699999988079071},{"id":"https://openalex.org/keywords/subjective-well-being","display_name":"subjective well-being","score":0.7850000262260437},{"id":"https://openalex.org/keywords/antipsychotic-tolerability","display_name":"antipsychotic tolerability","score":0.7630000114440918}],"concepts":[{"id":"https://openalex.org/C2779626651","wikidata":"https://www.wikidata.org/wiki/Q416545","display_name":"Asenapine","level":4,"score":0.9736394882202148},{"id":"https://openalex.org/C2776619155","wikidata":"https://www.wikidata.org/wiki/Q201872","display_name":"Olanzapine","level":3,"score":0.8623926043510437},{"id":"https://openalex.org/C2780325297","wikidata":"https://www.wikidata.org/wiki/Q834047","display_name":"Schizoaffective disorder","level":3,"score":0.8617037534713745},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.6638630628585815},{"id":"https://openalex.org/C61797465","wikidata":"https://www.wikidata.org/wiki/Q1188986","display_name":"Term (time)","level":2,"score":0.5427172183990479},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.5395054817199707},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.47851455211639404},{"id":"https://openalex.org/C2779727114","wikidata":"https://www.wikidata.org/wiki/Q170082","display_name":"Psychosis","level":2,"score":0.37109634280204773},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.3557681441307068},{"id":"https://openalex.org/C121332964","wikidata":"https://www.wikidata.org/wiki/Q413","display_name":"Physics","level":0,"score":0.0},{"id":"https://openalex.org/C62520636","wikidata":"https://www.wikidata.org/wiki/Q944","display_name":"Quantum mechanics","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000077152","descriptor_name":"Olanzapine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001569","descriptor_name":"Benzodiazepines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003986","descriptor_name":"Dibenzocycloheptenes","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006576","descriptor_name":"Heterocyclic Compounds, 4 or More Rings","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008137","descriptor_name":"Longitudinal Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011569","descriptor_name":"Psychiatric Status Rating Scales","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011618","descriptor_name":"Psychotic Disorders","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1055/s-0030-1248313","doi":"https://doi.org/10.1055/s-0030-1248313","is_oa":false,"landing_page_url":"https://doi.org/10.1055/s-0030-1248313","pdf_url":null,"source":{"id":"https://openalex.org/S4122505","display_name":"Pharmacopsychiatry","issn_l":"0176-3679","issn":["0176-3679","1439-0795"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320000","host_organization_name":"Thieme Medical Publishers (Germany)","host_organization_lineage":["https://openalex.org/P4310320000"],"host_organization_lineage_names":["Thieme Medical Publishers (Germany)"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacopsychiatry","raw_type":"journal-article"},{"id":"pmid:20205074","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20205074","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacopsychiatry","raw_type":"Clinical Trial, Phase III"},{"id":"pmid:22095218","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22095218","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacopsychiatry","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2123698193","https://openalex.org/W2501657165","https://openalex.org/W2323640127","https://openalex.org/W2133026967","https://openalex.org/W2551048401","https://openalex.org/W367366596","https://openalex.org/W2050370233","https://openalex.org/W2028840707","https://openalex.org/W2461679358","https://openalex.org/W2074203807"],"abstract_inverted_index":{"INTRODUCTION:":[0],"We":[1],"conducted":[2],"a":[3],"double-blind":[4],"1-year":[5],"trial":[6],"of":[7,54,113,129,154],"asenapine":[8,21,102,182],"in":[9,97,127,190],"patients":[10,114],"with":[11,43,46,78,82,93,101,120,171,178,181],"schizophrenia":[12],"or":[13,23,28],"schizoaffective":[14],"disorder.":[15],"METHODS:":[16],"Patients":[17],"were":[18,41,52,65,90,105,142],"randomized":[19],"to":[20,67],"(5":[22],"10":[24],"mg":[25,31],"BID;":[26],"n=913)":[27],"olanzapine":[29,104,121,161,179],"(10-20":[30],"QD;":[32],"n=312),":[33],"and":[34,58,103,107,139],"monitored":[35],"regularly.":[36],"RESULTS:":[37],"Trial":[38],"completion":[39],"rates":[40],"38%":[42],"asenapine,":[44,79],"57%":[45],"olanzapine;":[47],"main":[48],"reasons":[49],"for":[50],"discontinuation":[51],"withdrawal":[53],"consent":[55],"(22%,":[56],"16%)":[57],"insufficient":[59],"response":[60],"(25%,":[61],"14%);":[62],"fewer":[63],"discontinuations":[64],"due":[66],"adverse":[68,88],"events":[69,89],"(6%,":[70],"7%).":[71],"Mean":[72,95],"weight":[73,158],"gain":[74,159],"was":[75,148,176],"0.9":[76],"kg":[77,81],"4.2":[80],"olanzapine.":[83,130],"Extrapyramidal":[84],"symptoms":[85],"reported":[86],"as":[87],"more":[91,163],"common":[92],"asenapine.":[94],"reductions":[96],"PANSS":[98,167],"total":[99,168],"score":[100,169],"-21.0":[106],"-27.5":[108],"(":[109],"P<0.0001);":[110],"the":[111,125,133,174],"exclusion":[112],"who":[115],"had":[116],"previous":[117],"poor":[118],"experience":[119],"may":[122],"have":[123],"biased":[124],"results":[126],"favor":[128],"Scores":[131],"on":[132,136],"subjective":[134],"well-being":[135],"neuroleptics":[137],"scale":[138],"functionality":[140],"measures":[141],"similar":[143],"between":[144],"groups.":[145],"CONCLUSION:":[146],"Asenapine":[147],"well":[149],"tolerated":[150],"over":[151],"1":[152],"year":[153],"treatment,":[155],"causing":[156],"less":[157],"than":[160,180],"but":[162,188],"frequent":[164],"extrapyramidal":[165],"symptoms.":[166],"improved":[170],"both":[172],"agents;":[173],"improvement":[175],"greater":[177],"using":[183],"last":[184],"observations":[185],"carried":[186],"forward":[187],"not":[189],"an":[191],"observed-case":[192],"analysis.":[193]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2000406055","counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":7},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":8},{"year":2013,"cited_by_count":11},{"year":2012,"cited_by_count":15}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
